Merck (MRK) Invested Capital (2009 - 2026)

Merck (MRK) has reported Invested Capital for 18 consecutive years, with $2.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Invested Capital rose 79.71% year-over-year to $2.4 billion; the TTM figure through Mar 2026 stood at $7.9 billion (down 23.04% YoY), while the FY2025 annual figure was $2.6 billion, down 2.27% from the prior year.
• Invested Capital retreated to $2.4 billion in Q1 2026 per MRK's latest filing, from $2.6 billion in the prior quarter.
• Across five years, Invested Capital topped out at $3.1 billion in Q3 2024 and bottomed at $887.0 million in Q3 2023.
• Historically, Invested Capital has averaged $2.2 billion across 5 years, with a median of $2.4 billion in 2026.
• Annual changes were most pronounced in 2022 — Invested Capital plunged 83.34% — and 2024, when it jumped 255.02%.
• Merck's Invested Capital stood at $1.9 billion in 2022, then slipped by 29.5% to $1.4 billion in 2023, then soared by 93.08% to $2.6 billion in 2024, then retreated by 2.27% to $2.6 billion in 2025, then declined by 5.6% to $2.4 billion in 2026.
• Business Quant data shows MRK's Invested Capital at $2.4 billion in Q1 2026, $2.6 billion in Q4 2025, and $1.4 billion in Q3 2025.